Don’t want emails from us anymore? Click here to unsubscribe.

An analytics firm is surging on double-digit revenue gains and an AI push, a medical device maker is up 10% on a strong revenue beat, and a beverage stock has nearly tripled itself after sealing a major U.S. distribution deal. Here’s what’s moving the markets right now.

Next Big Pharma Move (Sponsored)

This Biotech Uplist Could Spark a Major Breakout

A biotech company doing $300M+ in annual revenue is rarely overlooked—but this one hasn’t even uplisted to a senior exchange yet.

That’s changing fast. The Form 10 has been filed with NASDAQ, and with a price target over 3x its current level (as of March 31), this could be one of the biggest moves of the quarter.

(By clicking the link above, you agree to receive emails from Huge Alerts. You can opt out at any time. - Privacy Policy)

The full stock alert drops Thursday. Timing is everything.

When the uplist lands, so could the momentum. Don’t miss your window.

[Click here to sign up before it hits.]

(By clicking the link above, you agree to receive emails from Huge Alerts. You can opt out at any time. - Privacy Policy)

Futures 📈

What to Watch

Earnings:

Economic Reports:

Wellness Market (Sponsored)

This Brain-Boosting Beverage Could Be the Next Monster

Monster Beverage delivered the best-performing stock of the 21st century—rising a staggering 137,100% since 2000. That’s more than Amazon, Apple, or Tesla.

Now, one under-the-radar company could be positioned to follow in those footsteps.

With a breakthrough energy drink enhanced by patented nootropics, it’s targeting the $73B+ functional beverage market with a formula built for both performance and profits.

It’s already backed by Orangetheory co-founder David Long—and it’s still early.

[Click here to read the full report and discover the company name.]

Technology

Cognyte Closes Fiscal Year with Solid Gains, Eyes $392M in FY26 Revenue

Cognyte Software Ltd. (NASDAQ: CGNT) reported robust fourth-quarter and full-year results for the fiscal year ending January 31, 2025, driven by strong product demand and improving margins.

Shares of the investigative analytics software company are soaring 8% in premarket trade.

For the fourth quarter, Cognyte posted $94.5 million in revenue, a 13% year-over-year increase.

Adjusted EBITDA more than doubled to $9.3 million, while non-GAAP operating income rose to $6.0 million from just $1.0 million a year ago.

Although GAAP net loss narrowed to $0.2 million, the improvement marks significant operational progress.

Full-year revenue reached $350.6 million, up 12% from fiscal 2024. Adjusted EBITDA surged to $29.1 million—more than tripling the previous year’s figure.

The company also cut its net loss to $7.2 million, down from $11.6 million.

Cognyte closed the fiscal year with $113.1 million in cash and reported $46.8 million in operating cash flow for the year.

Looking ahead, the company projects fiscal 2026 revenue to reach $392 million and expects adjusted EBITDA of $43 million, indicating continued margin expansion.

Non-GAAP EPS is expected to hit $0.16.

CEO Elad Sharon says the company is benefiting from expanded client relationships and a focus on AI-driven solutions. CFO David Abadi added that profitability in 2026 is set to outpace revenue growth, driven by operating efficiency and recurring revenue gains.

Technology

BlackBerry Projects Up to $534M in FY26 Revenue After Cylance Sale and Cloud Pivot

BlackBerry Ltd. (NYSE: BB) reported better-than-expected financial results for its fourth quarter and fiscal year ending February 28, 2025, underscoring strong momentum across its key business segments.

In Q4, total revenue reached $141.7 million, supported by a robust 74% adjusted gross margin.

Operating earnings (EBITDA) stood at $21.1 million, beating internal forecasts.

The company’s QNX software unit contributed $65.8 million in sales, while its Secure Communications segment generated $67.3 million. Licensing revenue added $8.6 million to the total.

For the full year, BlackBerry reported $534.9 million in revenue with $84.2 million in adjusted EBITDA.

QNX revenue climbed 10% year-over-year to $236 million, while Secure Communications brought in $272.6 million. Licensing revenue totaled $26.3 million.

In a key strategic move, BlackBerry completed the sale of its cybersecurity unit, Cylance, to Arctic Wolf, netting an initial $80 million in cash and strengthening its balance sheet.

The company also forged new partnerships, including one with Microsoft to bring its QNX platform to Azure, and launched collaborations with major players like AMD, Intel, and Vector.

Looking ahead, BlackBerry forecasts Q1 FY2026 revenue between $107 million and $115 million. Full-year revenue is expected to range between $504 million and $534 million.

CEO John J. Giamatteo called the fiscal year “transformational,” citing steady performance across divisions and key milestones like the Cylance divestiture.

Next Magnificent 7 (Sponsored)

Missed Apple and Tesla? Don’t Miss This

If you missed out on Apple, Tesla, or Amazon in their early days, you know how painful it is to watch those stocks skyrocket without you.

But here’s the good news—history is about to repeat itself.

We’ve identified 7 rapidly growing companies with the potential to become the next big market winners. These firms are innovating, expanding, and still flying under Wall Street’s radar—but not for long.

Get your FREE report: “The Next Magnificent 7 Stocks for 2025” right here.

(By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.)

Just like the original Magnificent Seven—Apple, Microsoft, Amazon, Alphabet, Nvidia, Meta, and Tesla—these companies are positioned for explosive growth. The key is getting in before the crowd.

Opportunities like this don’t last. Once the mainstream catches on, the biggest gains will be gone.

Click here to claim your free report and discover the next market leaders.

(By clicking the link above, you will get this free report and a free subscription to MarketBeat's daily email newsletter. You are also agreeing to the terms of our privacy policy. Unsubscribe at any time.)

Medical Equipment

MedTech Growth Drives AngioDynamics Shares Up 10%

Shares of AngioDynamics (NASDAQ: ANGO) are soaring this morning on stronger-than-expected fiscal third-quarter results and increased full-year forecast.

The medical device maker’s stock is up more than 10% in premarket trading.

For the quarter ending February 28, the company’s adjusted earnings are $0.03 per share. This is significantly ahead of analysts’ projections, who anticipated a loss of $0.11 per share.

Revenue is at $72 million, exceeding the consensus estimate of $70.57 million.

The standout performer this quarter was AngioDynamics' MedTech division, which includes its Auryon atherectomy and thrombus management devices.

Sales in this segment surged 22.2% year-over-year to $31.3 million, contributing meaningfully to the company’s overall growth.

CEO Jim Clemmer credited the company’s strong topline growth and positive adjusted EBITDA for the quarter’s outperformance.

He also highlighted the continued success of AngioDynamics’ portfolio in driving consistent progress throughout the fiscal year.

Looking ahead, the company has raised its full-year 2025 revenue projection to a range of $285 million to $288 million, slightly up from the previous estimate.

It also narrowed its expected adjusted earnings loss to between $0.31 and $0.34 per share, an improvement from prior guidance.

The results and revised outlook reflect AngioDynamics' growing momentum in the medical technology space and its improved operating efficiency.

Innovation Beverage Group Limited [IBG] - Last Close: $0.49

Innovation Beverage Group owns several bitters and premium beverage brands.

Its shares are up nearly 200% in premarket trading after announcing a major U.S. distribution deal with Republic National Distribution Company (RNDC), one of the country’s largest alcohol distributors, granting IBG access to key states including California and Michigan.

Sunshine Biopharma Inc. [SBFM] - Last Close: $2.08

Sunshine Biopharma is a pharmaceutical manufacturer.

SBFM is making waves in premarket trading after posting impressive 2024 results, reporting $34.9 million in revenue—a 45% jump from last year.

Sportsman's Warehouse Holdings, Inc. [SPWH] - Last Close: $0.97

Sportsman’s Warehouse is a go-to destination for outdoor gear, with a loyal customer base in hunting, fishing, and camping.

Shares are rising 40% in premarket trading after Sportsman’s posted better-than-expected same-store sales (down just 0.5% vs. 5% expected) and beat revenue forecasts.

Next-Gen Consumer Brands (Sponsored)

This New Energy Drink Could Be Wall Street’s Next Big Sip

Monster Beverage shocked the market with a 137,100% return—beating Amazon, Apple, and even Tesla.

Now, another beverage startup is generating serious buzz.

It’s not just another energy drink. This one’s infused with nootropics designed to support focus, clarity, and mood—exactly what today’s health-conscious consumers are demanding.

And the company behind it just brought on Orangetheory Fitness co-founder David Long as a board member. That kind of leadership rarely comes without serious conviction.

With a unique product, a booming category, and a proven industry heavyweight backing the mission, this could be the next beverage breakout story.

Click here to get the free special report with the name and details.

Everything Else

That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.

Best Regards,

— Adam Garcia
Elite Trade Club